Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
+3.94 (1.66%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 236.00 - 242.56
52 week 128.50 - 349.08
Open 236.13
Vol / Avg. 0.00/387,945.00
Mkt cap 5.81B
P/E     -
Div/yield     -
EPS -3.58
Shares 24.07M
Beta     -
Inst. own 75%
Aug 10, 2015
Q2 2015 Intercept Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 17, 2015
Intercept Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 10, 2015
Intercept Pharmaceuticals Inc at Goldman Sachs Healthcare Conference
May 19, 2015
Intercept Pharmaceuticals Inc at UBS Global Healthcare Conference
May 19, 2015
Intercept Pharmaceuticals Inc Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH Call
May 12, 2015
Intercept Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Intercept Pharmaceuticals Inc Earnings Call
May 11, 2015
Q1 2015 Intercept Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2724.91% -16262.21%
Operating margin -2743.72% -6497.98%
EBITD margin - -6472.56%
Return on average assets -46.75% -140.05%
Return on average equity -50.41% -180.80%
Employees 136 -
CDP Score - -


450 W 15th St Ste 505
NEW YORK, NY 10011-7082
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 50
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Lisa Bright chief commercial and corporate affairs officer
Age: 47
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 42
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Luca Benatti Ph.D Independent Director
Age: 54
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 41
Bio & Compensation  - Reuters